Descrizione Clinica
Cough Guaiacalcium complex scir200ml Sit
GUAIACALCIUM COMPLEX 0.144 G/100 ML + 2 G/100 ML SCIROP
active ingredients
100 ml of syrup contain: Dropropizine 0.144 g; potassium sulfoguaiacolate 2 g. Excipients with known effects: methyl para–hydroxybenzoate, sucrose, ethanol. For the full list of excipients, see paragraph 6.1.Excellent
Aconito root fluid extract, lauro ceraso (aromatic distillate water), wrinkle fluid extract, balm tolù extract fluid, ethanol 95%, natural caramel, aromatic extract, sucrose, methyl parahydroxybenzoate, purified water.Therapeutic indications
Cough sedative.Contraindications
• Hypersensitivity to active ingredients or any of the excipients listed in paragraph 6.1; • Pregnancy and nursing; • Children under the age of 13.Population
Population Adults and children over 13 years: 1 tablespoon 2–3 times a day. Method of administration In the cold season it is advisable to administer the hot syrup as a medicinal punch, diluting the dose in water, tea or milk very hot. Do not exceed the recommended doses.Conservation
None: Store at room temperature.Warnings
Guaiacalcium complex contains ethanol This medicine contains 6.3 vol. % of ethanol, e.g. up to 0,76 g per dose, equivalent to 20 ml of beer, 7.9 ml of wine per dose. Particular caution should therefore be used in administration to subjects with liver disease, alcoholism, epilepsy, traumas or brain diseases as well as in pregnant women. Guaiacalcium Complex contains methyl para–hydroxybenzoate It can cause allergic reactions (also delayed). Guaiacalcium Complex contains sucrose Patients with rare hereditary problems of fructose intolerance, glucose–galactose mal absorption, or isomaltase sucrasis failure, should not take this medicine.Interactions
Alcohol contained in the medicinal product may change or increase the effect of other drugs.Effects
Rarely reported nausea and other mild gastrointestinal disorders. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at: www.agenziafarmaco.gov.it/it/responsabili.Overdosing
In case of overdose, general anti-polying practices (gastric sink, activated carbon intake, parental administration of liquids, etc.) are to be applied.The drug should not be used during pregnancy and nursing.
Source: Farmadati
